bluebird bio Inc., a gene therapy company, has announced a restructuring plan aimed at optimizing its cost structure and achieving quarterly cash flow break-even in the second half of 2025. The restructuring is expected to result in a 20% reduction in cash operating expenses by the third quarter of 2025 compared to the previous reporting period.     The initiative also includes a workforce reduction of approximately 25%. To achieve cash flow break-even, bluebird anticipates scaling drug produc...